- Home
- OLO vs GERN Comparison
OLO vs GERN Comparison
Compare OLO & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLO
- GERN
- Stock Information
- Founded
- OLO 2005
- GERN 1990
- Country
- OLO United States
- GERN United States
- Employees
- OLO N/A
- GERN N/A
- Industry
- OLO Major Banks
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- OLO Finance
- GERN Health Care
- Exchange
- OLO Nasdaq
- GERN Nasdaq
- Market Cap
- OLO 1.0B
- GERN 853.5M
- IPO Year
- OLO 2021
- GERN 1996
- Fundamental
- Price
- OLO $8.47
- GERN $1.43
- Analyst Decision
- OLO Buy
- GERN Buy
- Analyst Count
- OLO 3
- GERN 9
- Target Price
- OLO $9.00
- GERN $5.13
- AVG Volume (30 Days)
- OLO 1.9M
- GERN 12.8M
- Earning Date
- OLO 05-08-2025
- GERN 05-07-2025
- Dividend Yield
- OLO N/A
- GERN N/A
- EPS Growth
- OLO N/A
- GERN N/A
- EPS
- OLO 0.01
- GERN N/A
- Revenue
- OLO $299,107,000.00
- GERN $116,293,000.00
- Revenue This Year
- OLO $19.60
- GERN $160.12
- Revenue Next Year
- OLO $17.69
- GERN $55.01
- P/E Ratio
- OLO $790.51
- GERN N/A
- Revenue Growth
- OLO 23.31
- GERN 22264.04
- 52 Week Low
- OLO $4.20
- GERN $1.17
- 52 Week High
- OLO $9.78
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- OLO 54.70
- GERN 51.74
- Support Level
- OLO $8.44
- GERN $1.30
- Resistance Level
- OLO $9.27
- GERN $1.60
- Average True Range (ATR)
- OLO 0.35
- GERN 0.12
- MACD
- OLO -0.13
- GERN 0.03
- Stochastic Oscillator
- OLO 6.06
- GERN 59.52
About OLO Olo Inc.
Olo Inc is an open Software as a Service platform for restaurants. Its platform powers restaurant brands' on-demand digital commerce operations, enabling digital ordering, delivery, front-of-house management, and payments, while further strengthening and enhancing restaurants' direct guest relationships. The company generates revenue from providing its customers access to its platform.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.